1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Implications Of 2seventy’s CAR-T Trial Pause Uncertain

 
• By Joseph Haas

Seattle Children’s, the biotech’s partner, halted a Phase I acute myeloid leukemia cell therapy trial due to a patient death following the start of a second dosing level cohort.

Halt
2seventy cell therapy trial halted following a patient death • Source: Shutterstock

An investigation into the study drug’s role is just getting started, but a Phase I clinical trial of 2seventy Bio, Inc.’s SC-DARIC33 chimeric antigen receptor T-cell (CAR-T) therapy candidate in acute myeloid leukemia was paused after a patient died. The bluebird bio spinout said on 14 June that its partner Seattle Children's Hospital & Medical Center placed the study on hold following a patient death in the second dose level of three scheduled doses to be tested in the PLAT-08 trial.

PLAT-08 is the first in-human trial of 2seventy’s Dimerizing Agent Regulated Immunoreceptor Complex (DARIC) technology, which it has said offers...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By Kevin Grogan

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Chinese Biotechs Sweep ADC Plus PD-(L)1/VEGF Bispecific Combos Into Phase II

 
• By Dexter Jie Yan

Chinese firms Junshi, Minghui and RemeGen rank among the world’s few players progressing antibody-drug conjugates combined with PD-(L)1/VEGF bispecific antibodies in Phase II trials for various cancers.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 
• By Alaric DeArment

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.

Pipeline Watch: Five Approvals And Twelve Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D

Pipeline Watch: Five Approvals And Twelve Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By Joseph Haas

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.